The FDA approved pralsetinib (Gavreto, Genentech/Blueprint Medicines) for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion–positive thyroid cancer who require systemic therapy and are radioactive iodine–refractory, if radioactive iodine is appropriate.
“Traditionally, we have treated patients with RET-altered thyroid cancers with multikinase inhibitors, nonselective therapies with